BioNTech (BNTX)
(Delayed Data from NSDQ)
$87.25 USD
+2.40 (2.83%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $87.26 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BNTX 87.25 +2.40(2.83%)
Will BNTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BNTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BNTX
Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View
Pfizer (PFE) Q2 Earnings Coming Up: What Should Investors Do?
BNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Other News for BNTX
J.P. Morgan Sticks to Their Sell Rating for BioNTech SE (BNTX)
BioNTech price target lowered by $3 at JPMorgan, here's why
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
Maravai cut at Morgan Stanley; Pfizer/BioNTech headwinds cited
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows